Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) have received a consensus rating of "Hold" from the eight research firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $18.71.
ATRA has been the topic of a number of recent research reports. The Goldman Sachs Group dropped their price objective on Atara Biotherapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a report on Tuesday, August 9th. Mizuho decreased their price objective on Atara Biotherapeutics from $39.00 to $31.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th. Finally, StockNews.com started coverage on Atara Biotherapeutics in a report on Wednesday, October 12th. They set a "hold" rating on the stock.
Get
Atara Biotherapeutics alerts:
Atara Biotherapeutics Stock Performance
ATRA stock opened at $4.65 on Tuesday. The company has a market capitalization of $441.19 million, a price-to-earnings ratio of -1.88 and a beta of 1.00. Atara Biotherapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $18.31. The stock has a fifty day moving average of $4.30 and a 200-day moving average of $4.74.
Insider Transactions at Atara Biotherapeutics
In other news, CFO Utpal Koppikar sold 6,255 shares of the business's stock in a transaction on Wednesday, November 16th. The stock was sold at an average price of $4.49, for a total value of $28,084.95. Following the completion of the transaction, the chief financial officer now owns 191,334 shares in the company, valued at $859,089.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
the SEC website. In related news, CEO Pascal Touchon sold 15,591 shares of Atara Biotherapeutics stock in a transaction on Wednesday, November 16th. The stock was sold at an average price of $4.49, for a total value of $70,003.59. Following the completion of the sale, the chief executive officer now owns 441,696 shares of the company's stock, valued at $1,983,215.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through
this hyperlink. Also, CFO Utpal Koppikar sold 6,255 shares of Atara Biotherapeutics stock in a transaction on Wednesday, November 16th. The stock was sold at an average price of $4.49, for a total value of $28,084.95. Following the completion of the sale, the chief financial officer now directly owns 191,334 shares of the company's stock, valued at approximately $859,089.66. The disclosure for this sale can be found
here. Insiders sold 29,800 shares of company stock worth $133,802 over the last quarter. 4.00% of the stock is currently owned by insiders.
Institutional Trading of Atara Biotherapeutics
Several hedge funds have recently bought and sold shares of ATRA. Envestnet Asset Management Inc. bought a new stake in Atara Biotherapeutics during the first quarter valued at about $112,000. New York State Common Retirement Fund boosted its stake in shares of Atara Biotherapeutics by 11.5% in the first quarter. New York State Common Retirement Fund now owns 64,445 shares of the biotechnology company's stock worth $599,000 after acquiring an additional 6,664 shares during the period. Qube Research & Technologies Ltd bought a new position in shares of Atara Biotherapeutics in the first quarter worth about $220,000. Teacher Retirement System of Texas boosted its stake in shares of Atara Biotherapeutics by 12.6% in the first quarter. Teacher Retirement System of Texas now owns 15,447 shares of the biotechnology company's stock worth $144,000 after acquiring an additional 1,728 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Atara Biotherapeutics by 12.5% in the first quarter. Swiss National Bank now owns 177,700 shares of the biotechnology company's stock worth $1,651,000 after acquiring an additional 19,800 shares during the period.
About Atara Biotherapeutics
(Get Rating)
Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.
Read More
- Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
- CrowdStrike Selloff: It's Time For Investors to Strike
- Pure Storage is a Steady Eddie Growing Storage Play
- Tesla Shares Are Sliding, Here's Why
- Insiders And Institutions Buy Fastenal, An Aristocrat To Be
- Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
